REDWOOD CITY, CA—Rose Geoffrey Beran, the Chief Commercial Officer of Pulmonx Corp (NASDAQ:LUNG), recently sold shares in a series of transactions totaling approximately $27,063. According to the SEC filing, these sales took place on December 2, 2024, and were conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs). The transaction comes as Pulmonx, currently valued at $258 million, demonstrates strong revenue growth of 22% year-over-year. InvestingPro analysis indicates the stock is currently undervalued, with a robust financial health score rated as "GOOD."
The transactions included the sale of 392 shares at $6.19 per share, totaling $2,426, and 690 shares at $6.18 per share, totaling $4,264. Additionally, Beran sold 1,756 shares at $6.19 per share, amounting to $10,869, and 1,538 shares at $6.18 per share, totaling $9,504.
Following these transactions, Beran retains direct ownership of 291,057 shares of Pulmonx Corp. The company's shares are traded on the NASDAQ under the ticker symbol LUNG.
In other recent news, Pulmonx Corporation reported a robust third-quarter performance, highlighted by a 15% year-over-year increase in worldwide sales, totaling $20.4 million. The U.S. market played a significant role, with revenues growing by 17%, while international sales also saw a rise of 12%. The company reaffirmed its full-year revenue guidance, indicating a strategic focus on physician training, patient workflow automation, and raising awareness of its Zephyr Valves for COPD treatment.
Pulmonx reported a net loss of $14.1 million for the quarter, despite a slight year-over-year improvement. However, the company managed to reduce its operating expenses by approximately $5 million, maintaining a steady gross margin at 74%. The company also made significant progress in its clinical trials, with the AeriSeal program set for commercial launch outside the U.S. in 2026 and within the U.S. in 2027.
These recent developments reflect Pulmonx's resilience and strategic foresight. The company's management remains optimistic about future growth, particularly in international markets, including China and Europe. As Pulmonx continues to execute its growth strategies, the market will be watching closely for its next moves, especially with the anticipated commercial launches of its AeriSeal program.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.